Myelodysplastic syndrome with ring sideroblasts
MONDO:0019157Acquired idiopathic sideroblastic anemia is one of a group of disorders known as the myelodysplastic syndromes (MDS) characterized by ineffective haemopoiesis affecting one or more blood cell lineages (myeloid, erythroid or megakaryocytic) leading to peripheral blood cytopenias and an increased risk of developing leukemia. Acquired idiopathic sideroblastic anemia is now more commonly referred to as refractory anemia with ringed sideroblasts or the acronym RARS.
Also known as: AISA, MDS with ring sideroblasts, MDS-RS, Pure sideroblastic Anaemia, Pure sideroblastic Anemia, RARS, acquired idiopathic sideroblastic anaemia, acquired idiopathic sideroblastic anemia
1591 clinical trials for this condition and its sub-types, 7 tagged with Myelodysplastic syndrome with ring sideroblasts itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for anemia patients: drug may cut need for blood transfusions
Disease control OngoingThis study tests a drug called luspatercept in people with anemia caused by myelodysplastic syndromes (MDS) or beta-thalassemia who need regular blood transfusions. The goal is to see if the drug is safe and can reduce the number of transfusions needed. About 85 participants in I…
Phase 4 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug combo shows promise for MDS and AML
Disease control OngoingThis study tests two drugs, vorinostat and azacitidine, together in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal is to find the best dose and see if the combination is safe and effective. About 135 participants will take part in this early-…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug may cut transfusions for MDS patients
Disease control OngoingThis study tests a drug called luspatercept in 70 adults with a low-risk form of MDS that causes anemia. The goal is to see if the drug can reduce the need for red blood cell transfusions. Participants receive the drug and are monitored for safety and effectiveness over time.
Phase 3 • Sponsor: GWT-TUD GmbH • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC